Table 3 Correlation of MSI status according to the clinicopathological data and RAS, PIK3CA, and BRAF mutations in our cohort.
From: Enhancing the landscape of colorectal cancer using targeted deep sequencing
Clinicopathological parameters | MSI statusa | |
|---|---|---|
MSS/MSI-L | MSI-H | |
Age | p = 0.1853 | |
≥ 60 | 54 (43.9%) | 7 (70.0%) |
< 60 | 69 (56.1%) | 3 (30.0%) |
Sex | p = 0.7448 | |
Male | 62 (50.4%) | 6 (60.0%) |
Female | 61 (49.6%) | 4 (40.0%) |
Tumor site | p = 0.009651 | |
Right colon | 34 (27.6%) | 7 (70.0%) |
Left colon | 89 (72.4%) | 3 (30.0%) |
T stage | p = 0.004249 | |
1, 2 | 7 (5.7%) | 4 (40.0%) |
3, 4 | 116 (94.3%) | 6 (60.0%) |
N stage | p = 0.002777 | |
0 | 27 (22.0%) | 7 (70.0%) |
1, 2 | 96 (78.0%) | 3 (30.0%) |
M stage | p = 0.08775 | |
0 | 72 (58.5%) | 9 (90.0%) |
1 | 51 (41.5%) | 1 (10.0%) |
Stage | p = 0.003935 | |
1, 2 | 20 (16.3%) | 6 (60.0%) |
3, 4 | 103 (83.7%) | 4 (40.0%) |
Differentiationb | p = 1 | |
Well/ Moderately | 102 (12.1%) | 9 (90.0%) |
Poorly | 14 (87.5%) | 1 (10.0%) |
Lymphatic invasionc | p = 0.7459 | |
Absent | 41 (35.7%) | 4 (40.0%) |
Present | 74 (64.3%) | 6 (60.0%) |
Vascular invasionc | p = 0.09041 | |
Absent | 70 (60.9%) | 9 (90.0%) |
Present | 45 (39.1%) | 1 (10.0%) |
Perineural invasionc | p = 0.02117 | |
Absent | 59 (51.3%) | 9 (90.0%) |
Present | 56 (48.7%) | 1 (10.0%) |
Initial CEA level (blood)d | p = 0.01908 | |
≥ 4 | 60 (50.0%) | 9 (90.0%) |
< 4 | 60 (50.0%) | 1 (10.0%) |
RAS mutation | p = 0.04454 | |
Absent | 54 (43.9%) | 8 (80.0%) |
Present | 69 (56.1%) | 2 (20.0%) |
PIK3CA mutation | p = 0.6935 | |
Absent | 96 (78.0%) | 7 (70.0%) |
Present | 27 (22.0%) | 3 (30.0%) |
BRAF mutation | p = 0.3277 | |
Absent | 119 (96.7%) | 9 (90.0%) |
Present | 4 (3.3%) | 1 (10.0%) |
